Targeting evolution: Could this be the next strategy to stop superbugs?

Nov 06, 2013

A Penn Medicine researcher is among the winners of a GlaxoSmithKline (GSK) "academic drug hunter" competition that will help fast track his lab's work to stop drug-resistant bacteria.

"Superbugs" are evolving faster than antibiotics can keep up with, and as a result more than 2 million people in the United States get infected every year, and at least 23,000 people die as a direct result.

With this new partnership, Rahul Kohli, MD, PhD, an assistant professor in the division of Infectious Diseases and department of Biochemistry and Biophysics at the Perelman School of Medicine at the University of Pennsylvania, and his lab can ramp up their efforts to discover drugs that stop the evolution in its tracks. Rather than taking the conventional approach of modifying existing antibiotics to overcome resistance, Kohli's lab aims to target the very pathways by which bacteria adapt to antibiotics and evolve resistance.

Kohli's team, spearheaded by Charlie Mo, a graduate student in Biochemistry and Molecular Biophysics, will now have access to 1.8 million compounds kept in GSK's chemical library and their other technologies.

"The search is on to find a molecule that can disrupt the pathway that allows bacteria to acquire ," Kohli said. "The hope is that such a molecule can make bacteria more sensitive to existing or slow the acquisition to the resistance, both of which would be valuable in the clinic."

This is GSK's first Discovery Fast Track competition in North America, which is designed to translate academic research into starting points for new potential medicines. There were eight winners in total across the country, selected from an initial pool of over 140 applications across 17 therapeutic areas and from 70 different institutions.

The competition was sponsored by GSK's Discovery Partnership with Academia program, a new approach to drug discovery where academic partners become core members of drug-hunting teams. GSK and the academic partner share the risk and reward of innovation: GSK funds activities in the partner laboratories and provides in-kind resources to progress a program from an idea to a candidate medicine.

"We were extremely pleased to be recognized," Kohli said. "Now we can take an idea that has good potential and efficiently move it from a theoretical academic pursuit into the practical realm, where it can hopefully ultimately benefit patients."

Work on the winning Discovery Fast Track projects will begin immediately and the first screens are expected to be completed in mid-2014. Kohli expects results from his investigation shortly thereafter.

Explore further: Researchers 'fish new pond' for antibiotics

add to favorites email to friend print save as pdf

Related Stories

GSK says sells thrombosis brands, French site

Sep 30, 2013

British drugs firm GlaxoSmithKline (GSK) said Monday that it has sold two thrombosis brands and a French plant to South African peer Aspen for £700 million ($1.13 billion, 834 million euros).

Recommended for you

Fighting bacteria—with viruses

Jul 24, 2014

Research published today in PLOS Pathogens reveals how viruses called bacteriophages destroy the bacterium Clostridium difficile (C. diff), which is becoming a serious problem in hospitals and healthcare institutes, due to its re ...

Atomic structure of key muscle component revealed

Jul 24, 2014

Actin is the most abundant protein in the body, and when you look more closely at its fundamental role in life, it's easy to see why. It is the basis of most movement in the body, and all cells and components ...

Brand new technology detects probiotic organisms in food

Jul 23, 2014

In the food industr, ity is very important to ensure the quality and safety of products consumed by the population to improve their properties and reduce foodborne illness. Therefore, a team of Mexican researchers ...

Protein evolution follows a modular principle

Jul 23, 2014

Proteins impart shape and stability to cells, drive metabolic processes and transmit signals. To perform these manifold tasks, they fold into complex three-dimensional shapes. Scientists at the Max Planck ...

Report on viruses looks beyond disease

Jul 22, 2014

In contrast to their negative reputation as disease causing agents, some viruses can perform crucial biological and evolutionary functions that help to shape the world we live in today, according to a new report by the American ...

User comments : 0